https://www.selleckchem.com/pe....ptide/octreotide-ace
Heterogeneity is an enormously complex problem because there are so many dimensions and variables that can be considered when assessing which ones may influence an efficacy or safety outcome for an individual patient. This is difficult in randomized controlled trials and even more so in observational settings. An alternative approach is presented in which the individual patient becomes the "subgroup," and similar patients are identified in the clinical trial database or electronic medical record that can be used to predict how
Мне нравится
Комментарий
Перепост
